Baseline characteristics

Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered

424 centres : patients

Not randomised Overall: of pts 10.5 IntoleranceHypotension Creatinine/Potassium rise Poor compliance Major clinical event Non medical reasons Unspecified %

Perindopril (mean  SD) Placebo Age (yrs) 60  9 Male (%) 8685 Weight (kg) 81   12 HR (bpm) 68  10 SBP (mmHg) 137   15 DBP (mmHg) 82  8 Baseline characteristics

Perindopril(%)Placebo (%) (%) Myocardial infarction Revascularisation Stroke / TIA Heart failure Peripheral vascular disease Medical history

Perindopril(%)Placebo (%) (%) Hypertension Diabetes mellitus Hypercholesterolaemia Current smoker Risk factors

Perindopril(%)Placebo(%) Platelet inhibitors  -blockers Lipid lowering drugs Nitrates Ca-blockers Diuretics Oral anticoagulants Baseline medication

Results

Primary endpoint % CV death, MI or cardiac arrest Placebo annual event rate: 2.4% Perindopril Placebo p = RRR: 20% Years

Primary and first secondary endpoint RRR (%) Perindopril better Placebo better CV mortality, MI, CA CV mortality Non fatal MI Cardiac arrest Total mortality, MI, UAP,CA

Sub-groups analysis RRR (%) Perindopril better Placebo better Previous MI No previous MI Age  56 yrs Age Age > 65 yrs Male Female

Sub-groups analysis Hypertension RRR (%) Perindopril better Placebo better No hypertension Diabetes mellitus No diabetes mellitus Stroke/TIA No stroke/TIA

92% patients on platelet inhibitors Sub-groups analysis RRR (%) Lipid lowering drug Perindopril better Placebo better No lipid lowering drug  -blockers No  -blockers Calcium blockers No calcium blockers

Secondary endpoints Fatal & non fatal MI, unstable angina Perindopril better Placebo better Total mortality, MI, UAP,CA CV mortality & MI CV mortality, MI & stroke CV mortality, MI, revascularisation CV mortality, MI, unstable angina Non fatal and fatal MI Total mortality CV mortality Unstable angina Cardiac arrest Stroke Revascularisation Heart failure RRR (%)

Fatal and non fatal MI Perindopril Placebo Years(%) p < RRR: 24%

Hospitalisation for heart failure Perindopril Placebo Years p = RRR: 39% (%)

-1/ Months mmHg Blood pressure  SBP: 5 mmHg  DBP: 2 mmHg Perindopril 8mg Placebo

Adherence to treatment Months (%)Placebo Perindopril 8mg

Withdrawal from treatment Perindopril%Placebo% Cough Hypotension Kidney failure Intolerance Study end-point Hypertension Refuse to continue Other reason